Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy
1 Division of Hematology and Oncology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA
2 Hollings Cancer Center, 86 Jonathan Lucas Street, Room# HO307, Charleston, SC, 29425, USA
Experimental Hematology & Oncology 2012, 1:20 doi:10.1186/2162-3619-1-20Published: 15 August 2012
Peripheral neuropathy (PN) is one of the most common side effects of bortezomib therapy. The majority of bortezomib-related PN is a sensory neuropathy of mild to moderate degree, and is reversible after dose reduction or discontinuation. However, occasionally bortezomib-induced neuropathy can be severe and affects motor and/or autonomic nerves, and may be mediated by immune process. The role of immune modulation therapy in the management of bortezomib-induced PN was not well established. Here, we reported a case of bortezomib-induced severe PN that responded well to plasma exchange and steroid treatment.